Taurochenodeoxycholic Acid

"Taurochenodeoxycholic Acid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A bile salt formed in the liver by conjugation of chenodeoxycholate with taurine, usually as the sodium salt. It acts as detergent to solubilize fats in the small intestine and is itself absorbed. It is used as a cholagogue and choleretic.

Descriptor ID	D013655
MeSH Number(s)	D02.455.326.146.100.850.875.900.875 D02.886.645.600.055.850.800.900.875 D04.210.500.105.225.272.150.850 D04.210.500.105.225.272.925.875 D04.210.500.105.225.900.900.870 D04.210.500.221.430.342.300.900 D04.210.500.221.430.342.900.910 D04.210.500.221.430.873.920.900
Concept/Terms	Taurochenodeoxycholic Acid Taurochenodeoxycholic Acid Acid, Taurochenodeoxycholic Chenodeoxycholyltaurine Taurine Chenodeoxycholate Taurine Chenodeoxycholate Chenodeoxycholate, Taurine Taurochenodeoxycholate

Below are MeSH descriptors whose meaning is more general than "Taurochenodeoxycholic Acid".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Hydrocarbons [D02.455]
Hydrocarbons, Acyclic [D02.455.326]
Alkanes [D02.455.326.146]
Alkanesulfonic Acids [D02.455.326.146.100]
Taurine [D02.455.326.146.100.850]
Taurocholic Acid [D02.455.326.146.100.850.875]
Taurodeoxycholic Acid [D02.455.326.146.100.850.875.900]
Taurochenodeoxycholic Acid [D02.455.326.146.100.850.875.900.875]
Sulfur Compounds [D02.886]
Sulfur Acids [D02.886.645]
Sulfonic Acids [D02.886.645.600]
Alkanesulfonic Acids [D02.886.645.600.055]
Taurine [D02.886.645.600.055.850]
Taurocholic Acid [D02.886.645.600.055.850.800]
Taurodeoxycholic Acid [D02.886.645.600.055.850.800.900]
Taurochenodeoxycholic Acid [D02.886.645.600.055.850.800.900.875]
Polycyclic Compounds [D04]
Fused-Ring Compounds [D04.210]
Steroids [D04.210.500]
Bile Acids and Salts [D04.210.500.105]
Cholic Acids [D04.210.500.105.225]
Deoxycholic Acid [D04.210.500.105.225.272]
Chenodeoxycholic Acid [D04.210.500.105.225.272.150]
Taurochenodeoxycholic Acid [D04.210.500.105.225.272.150.850]
Taurodeoxycholic Acid [D04.210.500.105.225.272.925]
Taurochenodeoxycholic Acid [D04.210.500.105.225.272.925.875]
Taurocholic Acid [D04.210.500.105.225.900]
Taurodeoxycholic Acid [D04.210.500.105.225.900.900]
Taurochenodeoxycholic Acid [D04.210.500.105.225.900.900.870]
Cholanes [D04.210.500.221]
Cholic Acids [D04.210.500.221.430]
Deoxycholic Acid [D04.210.500.221.430.342]
Chenodeoxycholic Acid [D04.210.500.221.430.342.300]
Taurochenodeoxycholic Acid [D04.210.500.221.430.342.300.900]
Taurodeoxycholic Acid [D04.210.500.221.430.342.900]
Taurochenodeoxycholic Acid [D04.210.500.221.430.342.900.910]
Taurocholic Acid [D04.210.500.221.430.873]
Taurodeoxycholic Acid [D04.210.500.221.430.873.920]
Taurochenodeoxycholic Acid [D04.210.500.221.430.873.920.900]

Below are MeSH descriptors whose meaning is related to "Taurochenodeoxycholic Acid".

Below are MeSH descriptors whose meaning is more specific than "Taurochenodeoxycholic Acid".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Taurochenodeoxycholic Acid" by people in this website by year, and whether "Taurochenodeoxycholic Acid" was a major or minor topic of these publications.

Bar chart showing 3 publications over 2 distinct years, with a maximum of 2 publications in 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2008	1	0	1
2020	2	0	2

Below are the most recent publications written about "Taurochenodeoxycholic Acid" by people in Profiles.

Paganoni S, Hendrix S, Dickson SP, Knowlton N, Macklin EA, Berry JD, Elliott MA, Maiser S, Karam C, Caress JB, Owegi MA, Quick A, Wymer J, Goutman SA, Heitzman D, Heiman-Patterson TD, Jackson CE, Quinn C, Rothstein JD, Kasarskis EJ, Katz J, Jenkins L, Ladha S, Miller TM, Scelsa SN, Vu TH, Fournier CN, Glass JD, Johnson KM, Swenson A, Goyal NA, Pattee GL, Andres PL, Babu S, Chase M, Dagostino D, Hall M, Kittle G, Eydinov M, McGovern M, Ostrow J, Pothier L, Randall R, Shefner JM, Sherman AV, St Pierre ME, Tustison E, Vigneswaran P, Walker J, Yu H, Chan J, Wittes J, Yu ZF, Cohen J, Klee J, Leslie K, Tanzi RE, Gilbert W, Yeramian PD, Schoenfeld D, Cudkowicz ME. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve. 2021 01; 63(1):31-39.

View in: PubMed
Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott MA, Maiser S, Karam C, Caress JB, Owegi MA, Quick A, Wymer J, Goutman SA, Heitzman D, Heiman-Patterson T, Jackson CE, Quinn C, Rothstein JD, Kasarskis EJ, Katz J, Jenkins L, Ladha S, Miller TM, Scelsa SN, Vu TH, Fournier CN, Glass JD, Johnson KM, Swenson A, Goyal NA, Pattee GL, Andres PL, Babu S, Chase M, Dagostino D, Dickson SP, Ellison N, Hall M, Hendrix K, Kittle G, McGovern M, Ostrow J, Pothier L, Randall R, Shefner JM, Sherman AV, Tustison E, Vigneswaran P, Walker J, Yu H, Chan J, Wittes J, Cohen J, Klee J, Leslie K, Tanzi RE, Gilbert W, Yeramian PD, Schoenfeld D, Cudkowicz ME. Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis. N Engl J Med. 2020 09 03; 383(10):919-930.

View in: PubMed
Macedo B, Batista AR, Ferreira N, Almeida MR, Saraiva MJ. Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of Familial Amyloidotic Polyneuropathy. Biochim Biophys Acta. 2008 Sep; 1782(9):517-22.

View in: PubMed

People

Explore

Similar Concepts

Top Journals